The role of flumazenil infusion in the treatment of alcohol withdrawal
Go Medical Industries Pty Ltd
45 participants
Feb 24, 2016
Interventional
Conditions
Summary
Alcohol detoxification is associated with a myriad of withdrawal symptoms ranging from headaches and nausea to anxiety and potential seizures. Typically relief for these withdrawal symptoms involves treatment with benzodiazepines, which come with their own set of associated risks. Benzodiazepines have a high potential for dependence as well as cognitive and psychomotor impairment. Flumazenil, conventionally viewed as a benzodiazepine antagonist with agonist actions having been observed at low doses, has demonstrated potential as a management tool to assist both alcohol and benzodiazepine withdrawal. This study aims to assess the efficacy and safety of low-dose flumazenil infusion administered subcutaneously as an option for detoxification from alcohol. It will also explore the role of flumazenil-assisted alcohol withdrawal in maintaining abstinence post-withdrawal.
Eligibility
Inclusion Criteria1
- Participants will be patients of Fresh Start Recovery Programme who are receiving naltrexone implant treatment for problematic alcohol use. To be included in the study, patients must score 22 or higher on the Alcohol Dependence Scale (Skinner & Allen, 1982) and have the desire to cease alcohol consumption.
Exclusion Criteria1
- Patients will be excluded if they suffer epilepsy or have a history of seizures or fitting, are pregnant or are breastfeeding, are co-dependent on benzodiazepines, are under 18 years of age or are unable or unwilling to provide informed consent.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
A double-blind placebo-controlled randomised clinical trial of a 96-hour continuous subcutaneous infusion of flumazenil 16 mg (approx. 167mcg/hr) for the treatment of alcohol withdrawal syndrome. Arm 1: 96-hour continuous subcutaneous infusion of flumazenil 16 mg (approx. 167mcg/hr) plus oral diazepam 10-20 mg hourly as required. The requirement for diazepam will be determined by patient carers using the CIWA-Ar scale as follows; no diazepam to be given for a score less than or equal to 7, diazepam 10 mg for a score between 8 and 14 inclusive and diazepam 20 mg for a score of 15 or higher.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12617000039381